Travere Therapeutics (TVTX) Operating Income (2016 - 2025)
Historic Operating Income for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $24.9 million.
- Travere Therapeutics' Operating Income rose 14440.15% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.1 million, marking a year-over-year increase of 7449.65%. This contributed to the annual value of -$323.8 million for FY2024, which is 1656.91% up from last year.
- Per Travere Therapeutics' latest filing, its Operating Income stood at $24.9 million for Q3 2025, which was up 14440.15% from -$12.6 million recorded in Q2 2025.
- Over the past 5 years, Travere Therapeutics' Operating Income peaked at $24.9 million during Q3 2025, and registered a low of -$139.2 million during Q1 2024.
- In the last 5 years, Travere Therapeutics' Operating Income had a median value of -$72.0 million in 2022 and averaged -$66.4 million.
- Its Operating Income has fluctuated over the past 5 years, first tumbled by 21558.37% in 2021, then surged by 14440.15% in 2025.
- Quarter analysis of 5 years shows Travere Therapeutics' Operating Income stood at -$84.8 million in 2021, then fell by 2.18% to -$86.7 million in 2022, then fell by 8.69% to -$94.2 million in 2023, then skyrocketed by 35.55% to -$60.7 million in 2024, then surged by 141.05% to $24.9 million in 2025.
- Its Operating Income was $24.9 million in Q3 2025, compared to -$12.6 million in Q2 2025 and -$42.7 million in Q1 2025.